BostonGene and Unilever are starting a strategic collaboration in scientific exploration and long-term innovation. As developer of an artificial intelligence (AI) foundation model for tumor and immune biology, BostonGene will leverage proprietary analytical capabilities.

Unilever, meanwhile, is a leader in consumer goods, with its products used daily by 3.7 billion people in 190 countries. To that scientific expertise, BostonGene plans to add omnimodal data integration and advanced AI capacity.

Unilever Takes Leap With AI

Altogether, the collaboration seeks examination of scientific factors shaping individual differences in biology. By identifying these insights, BostonGene and Unilever hope to promote future breakthroughs in product development.

“Our foundation model was built to unlock the full potential of biology,” said BostonGene Chief Medical Officer Nathan Fowler, MD.

Fowler said data holds the key to that unlocking, and the collaboration extends the model beyond oncology.

“[It uses] advanced AI to accelerate discoveries that will help shape the future of consumer-focused science and innovation,” Fowler added.

Samantha Samaras, Unilever Vice President for Science and Technology—R&D and Personal Care, said Unilever is investing in cutting-edge science.

“This partnership with BostonGene will allow us to apply advanced AI and multiomics approaches to generate new insights,” Samaras said.

By doing so, Samaras added, the collaboration wants to “inspire the next generation of pioneering science-based innovations for [Unilever’s] consumers.”

Other BostonGene Deals

BostonGene has a few other collaborations in the works early in 2026. In January, the company announced a partnership with AstraZeneca to advance oncology drug development using BostonGene’s multimodal AI platform.

Then in February, BostonGene and Daiichi Sankyo unveiled a new collaboration. This one aims to integrate AI-driven translational intelligence into an antibody-drug conjugate development program.